UA94924C2 - Композиция гликозилованного альфа-фетопротеина и индукторов апоптоза для лечения рака - Google Patents

Композиция гликозилованного альфа-фетопротеина и индукторов апоптоза для лечения рака Download PDF

Info

Publication number: UA94924C2
Authority: UA; Ukraine
Prior art keywords: aer; apoptosis; cancer; glycosylated; app
Prior art date: 2005-11-15

Application number

UAA200808027A

Other languages

English (en)

Ukrainian (uk)

Inventor

Владимир Пак

Original Assignee

Констеб Фармасьютикал, Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-15

Filing date

2006-11-15

Publication date

2011-06-25

2006-11-15 Application filed by Констеб Фармасьютикал, Инк. filed Critical Констеб Фармасьютикал, Инк.

2011-06-25 Publication of UA94924C2 publication Critical patent/UA94924C2/ru

Links

239000000203 mixture Substances 0.000 title claims abstract description 118
230000006907 apoptotic process Effects 0.000 title claims abstract description 114
206010028980 Neoplasm Diseases 0.000 title claims abstract description 95
201000011510 cancer Diseases 0.000 title claims abstract description 62
108010026331 alpha-Fetoproteins Proteins 0.000 title claims abstract description 45
102000013529 alpha-Fetoproteins Human genes 0.000 title claims abstract 32
239000000411 inducer Substances 0.000 title description 6
239000003795 chemical substances by application Substances 0.000 claims abstract description 122
230000001939 inductive effect Effects 0.000 claims abstract description 80
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 56
238000000034 method Methods 0.000 claims abstract description 32
239000012190 activator Substances 0.000 claims abstract description 23
210000001700 mitochondrial membrane Anatomy 0.000 claims abstract description 17
210000004381 amniotic fluid Anatomy 0.000 claims abstract description 15
238000000605 extraction Methods 0.000 claims abstract description 15
230000002438 mitochondrial effect Effects 0.000 claims abstract description 15
210000004369 blood Anatomy 0.000 claims abstract description 14
239000008280 blood Substances 0.000 claims abstract description 14
108090000566 Caspase-9 Proteins 0.000 claims abstract description 13
239000002555 ionophore Substances 0.000 claims abstract description 12
230000000236 ionophoric effect Effects 0.000 claims abstract description 12
239000011148 porous material Substances 0.000 claims abstract description 12
108090000397 Caspase 3 Proteins 0.000 claims abstract description 4
102100029855 Caspase-3 Human genes 0.000 claims abstract description 4
230000002401 inhibitory effect Effects 0.000 claims abstract 3
210000004027 cell Anatomy 0.000 claims description 67
QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims description 55
QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 54
CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 54
DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 54
PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 54
MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 54
FYQXODZRNSCOTR-UHFFFAOYSA-N atractyloside Natural products O1C(CO)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OC(=O)CC(C)C)C1OC1CC2(C)C3CCC(C(=C)C4O)CC34CCC2C(C(O)=O)C1 FYQXODZRNSCOTR-UHFFFAOYSA-N 0.000 claims description 19
IUCNQFHEWLYECJ-FNAJZLPOSA-L Atractyloside Chemical group [K+].[K+].O1[C@H](CO)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](OC(=O)CC(C)C)[C@@H]1O[C@H]1C[C@@]2(C)[C@@H]3CC[C@@H](C(=C)[C@@H]4O)C[C@]34CC[C@@H]2[C@H](C(O)=O)C1 IUCNQFHEWLYECJ-FNAJZLPOSA-L 0.000 claims description 17
206010009944 Colon cancer Diseases 0.000 claims description 15
HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 14
-1 Cpa437 Chemical compound 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 13
208000029742 colonic neoplasm Diseases 0.000 claims description 13
230000035699 permeability Effects 0.000 claims description 13
239000006228 supernatant Substances 0.000 claims description 13
IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 claims description 13
102000004039 Caspase-9 Human genes 0.000 claims description 12
208000032839 leukemia Diseases 0.000 claims description 12
230000035935 pregnancy Effects 0.000 claims description 11
239000002775 capsule Substances 0.000 claims description 10
239000000463 material Substances 0.000 claims description 10
239000012071 phase Substances 0.000 claims description 10
WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims description 9
229960003538 lonidamine Drugs 0.000 claims description 9
206010006187 Breast cancer Diseases 0.000 claims description 8
208000026310 Breast neoplasm Diseases 0.000 claims description 8
206010048723 Multiple-drug resistance Diseases 0.000 claims description 8
210000001072 colon Anatomy 0.000 claims description 8
208000016691 refractory malignant neoplasm Diseases 0.000 claims description 8
238000000926 separation method Methods 0.000 claims description 8
241000282412 Homo Species 0.000 claims description 7
210000002257 embryonic structure Anatomy 0.000 claims description 7
239000002994 raw material Substances 0.000 claims description 7
229940080817 rotenone Drugs 0.000 claims description 7
JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 claims description 7
238000003756 stirring Methods 0.000 claims description 6
HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 5
239000008346 aqueous phase Substances 0.000 claims description 5
GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 5
239000002244 precipitate Substances 0.000 claims description 5
230000035755 proliferation Effects 0.000 claims description 5
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 4
ZQLBCAUKNYXILZ-UGKGYDQZSA-N Piericidin A Natural products COc1nc(CC=C(/C)C=CCC(=C[C@H](C)[C@@H](O)C(=CC)C)C)c(C)c(O)c1OC ZQLBCAUKNYXILZ-UGKGYDQZSA-N 0.000 claims description 4
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 claims description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
229960003957 dexamethasone Drugs 0.000 claims description 4
201000001441 melanoma Diseases 0.000 claims description 4
BBLGCDSLCDDALX-LKGBESRRSA-N piericidin A Chemical compound COC=1NC(C\C=C(/C)C\C=C\C(\C)=C\[C@@H](C)[C@@H](O)C(\C)=C\C)=C(C)C(=O)C=1OC BBLGCDSLCDDALX-LKGBESRRSA-N 0.000 claims description 4
229940088594 vitamin Drugs 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
229930003231 vitamin Natural products 0.000 claims description 4
235000013343 vitamin Nutrition 0.000 claims description 4
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 3
241000282472 Canis lupus familiaris Species 0.000 claims description 3
241000283086 Equidae Species 0.000 claims description 3
241000282326 Felis catus Species 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
241001494479 Pecora Species 0.000 claims description 3
241000288906 Primates Species 0.000 claims description 3
208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
206010057644 Testis cancer Diseases 0.000 claims description 3
229960005280 isotretinoin Drugs 0.000 claims description 3
210000001161 mammalian embryo Anatomy 0.000 claims description 3
201000003120 testicular cancer Diseases 0.000 claims description 3
206010005003 Bladder cancer Diseases 0.000 claims description 2
206010014733 Endometrial cancer Diseases 0.000 claims description 2
206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
101100247316 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-1 gene Proteins 0.000 claims description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
206010060862 Prostate cancer Diseases 0.000 claims description 2
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 2
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 2
201000007270 liver cancer Diseases 0.000 claims description 2
208000014018 liver neoplasm Diseases 0.000 claims description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
201000002528 pancreatic cancer Diseases 0.000 claims description 2
208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
206010038038 rectal cancer Diseases 0.000 claims description 2
201000001275 rectum cancer Diseases 0.000 claims description 2
201000000849 skin cancer Diseases 0.000 claims description 2
201000002510 thyroid cancer Diseases 0.000 claims description 2
201000005112 urinary bladder cancer Diseases 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 3
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010038389 Renal cancer Diseases 0.000 claims 1
201000010982 kidney cancer Diseases 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
150000004492 retinoid derivatives Chemical class 0.000 claims 1
230000013020 embryo development Effects 0.000 abstract description 6
230000036457 multidrug resistance Effects 0.000 abstract description 3
102100026550 Caspase-9 Human genes 0.000 abstract 1
239000008191 permeabilizing agent Substances 0.000 abstract 1
239000003814 drug Substances 0.000 description 39
229940079593 drug Drugs 0.000 description 37
238000002591 computed tomography Methods 0.000 description 33
210000004185 liver Anatomy 0.000 description 33
206010027476 Metastases Diseases 0.000 description 27
230000002354 daily effect Effects 0.000 description 27
230000000694 effects Effects 0.000 description 27
241000282414 Homo sapiens Species 0.000 description 25
102000005962 receptors Human genes 0.000 description 24
108020003175 receptors Proteins 0.000 description 24
208000009956 adenocarcinoma Diseases 0.000 description 21
239000002246 antineoplastic agent Substances 0.000 description 19
241000699670 Mus sp. Species 0.000 description 18
239000000243 solution Substances 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
210000004881 tumor cell Anatomy 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
230000009401 metastasis Effects 0.000 description 15
238000002360 preparation method Methods 0.000 description 14
102100023635 Alpha-fetoprotein Human genes 0.000 description 13
102000011727 Caspases Human genes 0.000 description 13
108010076667 Caspases Proteins 0.000 description 13
238000003759 clinical diagnosis Methods 0.000 description 13
238000011081 inoculation Methods 0.000 description 13
229940127089 cytotoxic agent Drugs 0.000 description 12
230000007423 decrease Effects 0.000 description 10
238000011161 development Methods 0.000 description 10
230000018109 developmental process Effects 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
230000004044 response Effects 0.000 description 10
238000002512 chemotherapy Methods 0.000 description 9
239000000499 gel Substances 0.000 description 9
230000006641 stabilisation Effects 0.000 description 9
238000011105 stabilization Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
206010061289 metastatic neoplasm Diseases 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
230000012010 growth Effects 0.000 description 7
230000036961 partial effect Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
230000004614 tumor growth Effects 0.000 description 7
229940041181 antineoplastic drug Drugs 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000002254 cytotoxic agent Substances 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
230000001605 fetal effect Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
210000003470 mitochondria Anatomy 0.000 description 6
230000009467 reduction Effects 0.000 description 6
238000002271 resection Methods 0.000 description 6
206010047700 Vomiting Diseases 0.000 description 5
238000011026 diafiltration Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
102000009027 Albumins Human genes 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
241001529936 Murinae Species 0.000 description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
229960002594 arsenic trioxide Drugs 0.000 description 4
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
230000008823 permeabilization Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
108010078791 Carrier Proteins Proteins 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
235000013399 edible fruits Nutrition 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000008693 nausea Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
QPRQJOHKNJIMGN-CPQVXFHYSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-3',13,17,23-tetron Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@@]12O[C@H](CC(C)O)[C@H](C)CC1=O QPRQJOHKNJIMGN-CPQVXFHYSA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 2
CRCWPKGKPRVXAP-UHFFFAOYSA-N 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 CRCWPKGKPRVXAP-UHFFFAOYSA-N 0.000 description 2
101100479620 Arabidopsis thaliana OVA2 gene Proteins 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 2
GAAKALASJNGQKD-UHFFFAOYSA-N LY-165163 Chemical compound C1=CC(N)=CC=C1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 GAAKALASJNGQKD-UHFFFAOYSA-N 0.000 description 2
206010024305 Leukaemia monocytic Diseases 0.000 description 2
QPRQJOHKNJIMGN-UHFFFAOYSA-N Oligomycin B Natural products CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21OC(CC(C)O)C(C)CC2=O QPRQJOHKNJIMGN-UHFFFAOYSA-N 0.000 description 2
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
241000282887 Suidae Species 0.000 description 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229910052785 arsenic Inorganic materials 0.000 description 2
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
229910052793 cadmium Inorganic materials 0.000 description 2
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
235000017663 capsaicin Nutrition 0.000 description 2
229960002504 capsaicin Drugs 0.000 description 2
230000030833 cell death Effects 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
235000012754 curcumin Nutrition 0.000 description 2
229940109262 curcumin Drugs 0.000 description 2
239000004148 curcumin Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000001723 extracellular space Anatomy 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
102000046783 human APP Human genes 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
239000011133 lead Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000004898 mitochondrial function Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000006894 monocytic leukemia Diseases 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
239000012053 oil suspension Substances 0.000 description 2
QPRQJOHKNJIMGN-WVUAJZTGSA-N oligomycin B Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@]12O[C@@H](C[C@@H](C)O)[C@@H](C)CC1=O QPRQJOHKNJIMGN-WVUAJZTGSA-N 0.000 description 2
QPRQJOHKNJIMGN-UXAQBZNTSA-N oligomycin b Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@@]12O[C@H](C[C@H](C)O)[C@H](C)CC1=O QPRQJOHKNJIMGN-UXAQBZNTSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
229960001285 quercetin Drugs 0.000 description 2
235000005875 quercetin Nutrition 0.000 description 2
230000003134 recirculating effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000013060 ultrafiltration and diafiltration Methods 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
235000019155 vitamin A Nutrition 0.000 description 2
239000011719 vitamin A Substances 0.000 description 2
229940045997 vitamin a Drugs 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
108091007065 BIRCs Proteins 0.000 description 1
235000018185 Betula X alpestris Nutrition 0.000 description 1
235000018212 Betula X uliginosa Nutrition 0.000 description 1
241001520764 Betula pubescens Species 0.000 description 1
235000018222 Betula pubescens ssp. pubescens Nutrition 0.000 description 1
235000018982 Betula pubescens subsp tortuosa Nutrition 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
210000003771 C cell Anatomy 0.000 description 1
101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 1
HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
QLAKAJLYYGOZQL-UHFFFAOYSA-N Carboxyphosphamide Chemical compound ClCCN(CCCl)P(=O)(N)OCCC(O)=O QLAKAJLYYGOZQL-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001331845 Equus asinus x caballus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
206010027452 Metastases to bone Diseases 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
206010027459 Metastases to lymph nodes Diseases 0.000 description 1
101100111630 Mus musculus Naip1 gene Proteins 0.000 description 1
241000088844 Nothocestrum Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
108010067973 Valinomycin Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
229940091658 arsenic Drugs 0.000 description 1
AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 1
FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000006177 biological buffer Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
229930195731 calicheamicin Natural products 0.000 description 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
229940127068 carboxycyclophosphamide Drugs 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
229930188550 carminomycin Natural products 0.000 description 1
XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
229950001725 carubicin Drugs 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000003630 growth substance Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000005868 ontogenesis Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000003075 phytoestrogen Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 1
229960005080 warfarin Drugs 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Marine Sciences & Fisheries (AREA)
Gastroenterology & Hepatology (AREA)
Pregnancy & Childbirth (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

UAA200808027A 2005-11-15 2006-11-15 Композиция гликозилованного альфа-фетопротеина и индукторов апоптоза для лечения рака UA94924C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11/274,906 US20070111936A1 (en)	2005-11-15	2005-11-15	Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer

Publications (1)

Publication Number	Publication Date
UA94924C2 true UA94924C2 (ru)	2011-06-25

Family

ID=38041700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200808027A UA94924C2 (ru)	2005-11-15	2006-11-15	Композиция гликозилованного альфа-фетопротеина и индукторов апоптоза для лечения рака

Country Status (9)

Country	Link
US (2)	US20070111936A1 (ru)
EP (1)	EP1959978B1 (ru)
JP (1)	JP2009515909A (ru)
KR (1)	KR20080067376A (ru)
CN (1)	CN101437531A (ru)
CA (1)	CA2669549A1 (ru)
RU (1)	RU2438695C2 (ru)
UA (1)	UA94924C2 (ru)
WO (1)	WO2007056852A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010003232A1 (en) *	2008-07-07	2010-01-14	Constab Pharmaceutical Inc.	Treating cancer using atractyloside
AU2010309438A1 (en) *	2009-10-22	2012-06-07	Ricardo J. Moro	Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof
DK2822558T3 (da)	2012-03-06	2020-03-23	The Board Of Trustees Of The Univ Of Illionis	Procaspase 3 aktivering ved hjælp af kombinations terapi
CA2866020C (en)	2012-03-06	2020-09-22	The Board Of Trustees Of The University Of Illinois	Procaspase combination therapy for glioblastoma
CN105188716B (zh) *	2012-11-13	2019-02-22	河谷控股Ip有限责任公司	钙通量激动剂及其方法
FI20130341A7 (fi)	2013-11-19	2015-05-20	Oy Safemed Ltd	Huonosti vesiliukoisten lääkeaineiden kuljetus metalli-ioneilla tasapainotetun alfafetoproteiinin mukana
US10179120B2 (en) *	2014-01-06	2019-01-15	Iron Therapeutics Holdings Ag	Dosage regimen of ferric trimaltol
GB201418710D0 (en)	2014-10-21	2014-12-03	Iron Therapeutics Holdings Ag	Dosage regimen
WO2016119045A1 (en) *	2015-01-28	2016-08-04	University Health Network	Drug complexes comprising aipha-fetoprotein
RU2642957C2 (ru) *	2016-03-11	2018-01-29	Федеральное государственное бюджетное учреждение науки Уральский научно-практический центр радиационной медицины ФМБА России (ФГБУН УНПЦ РМ ФМБА России)	Липосома, фармацевтическая композиция и лекарственное средство для лечения местных радиационных поражений кожи, применение липосом и способ для лечения местных радиационных поражений кожи
CN106581021B (zh) *	2016-11-17	2020-04-21	浙江省医学科学院	苍术苷和5-氟尿嘧啶联合在制备预防和治疗直肠癌药物中的应用
SG11202004384YA (en)	2017-11-17	2020-06-29	Univ Illinois	Cancer therapy by degrading dual mek signaling
RU2665922C1 (ru) *	2018-04-24	2018-09-05	Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Казанский научный центр Российской академии наук"	Фосфониевые соли на основе бетулиновой кислоты, обладающие цитотоксической активностью в отношении аденокарциномы предстательной железы
KR20210084442A (ko)	2018-10-05	2021-07-07	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	포도막 흑색종 치료를 위한 병용 요법
WO2026077374A1 (en) *	2024-10-09	2026-04-16	Centre for Translational Stem Cell Biology Limited	Composition and methods of safety testing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6534479B1 (en)	1995-01-24	2003-03-18	Martinex R & D Inc.	Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers
SE9802162D0 (sv) *	1998-06-17	1998-06-17	Nomet Management Services Bv	Immunostimulating composition
RU2179452C1 (ru) *	2000-06-22	2002-02-20	Пак Владимир Николаевич	Способ лечения злокачественных новообразований и комплексный препарат, обладающий противоопухолевым действием, для осуществления способа
WO2002016395A1 (en)	2000-08-18	2002-02-28	The Board Of Trustees Of The University Of Illinois	Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
EA011606B1 (ru) *	2004-07-14	2009-04-28	Эдуард Борисович Татулов	Способы получения и применения рекомбинантного альфа-фетопротеина
US7981917B2 (en)	2007-03-26	2011-07-19	University Of Southern California	Methods and compositions for including apoptosis by stimulating ER stress

2005
- 2005-11-15 US US11/274,906 patent/US20070111936A1/en not_active Abandoned
2006
- 2006-11-15 EP EP06804732.3A patent/EP1959978B1/en not_active Not-in-force
- 2006-11-15 UA UAA200808027A patent/UA94924C2/ru unknown
- 2006-11-15 WO PCT/CA2006/001867 patent/WO2007056852A1/en not_active Ceased
- 2006-11-15 US US12/093,842 patent/US8071547B2/en active Active - Reinstated
- 2006-11-15 RU RU2008123804/15A patent/RU2438695C2/ru not_active IP Right Cessation
- 2006-11-15 CA CA002669549A patent/CA2669549A1/en not_active Abandoned
- 2006-11-15 KR KR1020087013966A patent/KR20080067376A/ko not_active Ceased
- 2006-11-15 JP JP2008540415A patent/JP2009515909A/ja active Pending
- 2006-11-15 CN CNA2006800510671A patent/CN101437531A/zh active Pending

Also Published As

Publication number	Publication date
US20080318840A1 (en)	2008-12-25
KR20080067376A (ko)	2008-07-18
RU2008123804A (ru)	2009-12-27
CN101437531A (zh)	2009-05-20
EP1959978A4 (en)	2009-12-09
EP1959978B1 (en)	2015-12-30
RU2438695C2 (ru)	2012-01-10
JP2009515909A (ja)	2009-04-16
US20070111936A1 (en)	2007-05-17
US8071547B2 (en)	2011-12-06
WO2007056852A1 (en)	2007-05-24
CA2669549A1 (en)	2007-05-24
EP1959978A1 (en)	2008-08-27

Publication	Publication Date	Title
Song et al.	2018	Phase I trial of selenium plus chemotherapy in gynecologic cancers
UA94924C2 (ru)	2011-06-25	Композиция гликозилованного альфа-фетопротеина и индукторов апоптоза для лечения рака
Koval et al.	2012	A novel pro-apoptotic effector lactaptin inhibits tumor growth in mice models
Hu et al.	2025	Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors
Ohman et al.	2016	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic
CN104415298A (zh)	2015-03-18	用于制造供化疗癌症患者使用的辅助治疗剂的组合物
EP4445914A1 (en)	2024-10-16	Pharmaceutical composition for treating tumors and use
CN104013640A (zh)	2014-09-03	褐藻糖胶在制备治疗恶病质及癌症的药物中的应用
Zhang et al.	2021	Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma
Zhao et al.	2022	Biomimetic cytomembrane-coated ZIF-8-loaded DMDD nanoparticle and sonodynamic co-therapy for cancer
Da et al.	2023	Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers
EP3650028A1 (en)	2020-05-13	Compositions and methods for reducing or preventing metastasis
KR20240164794A (ko)	2024-11-20	암 치료를 위한 병용 요법
CN108778336A (zh)	2018-11-09	一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途
WO2022134433A1 (zh)	2022-06-30	一种组合物及其在治疗肿瘤中的应用
CN119564691A (zh)	2025-03-07	氯法齐明在制备治疗癌症的药物中的应用
KR20140035974A (ko)	2014-03-24	종양 질환 치료를 위한 약제 조성물
Zeng et al.	2023	Synergistic glycolysis disturbance for cancer therapy by a MOF-based nanospoiler
EP4104823A1 (en)	2022-12-21	Inhibitor of aspartic acid synthesis in tumor cells, inhibitor of spheroid formation of tumor cells, inhibitor of tumor cell metastasis, activity enhancer of glycolytic inhibitor, and pharmaceutical composition for suppressing and/or preventing tumor metastasis
TW201834650A (zh)	2018-10-01	哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
Sun et al.	2024	Combretastatin A4 phosphate encapsulated in hyaluronic acid nanoparticles is highly cytotoxic to oral squamous cell carcinoma
Luo et al.	2024	Effect of quercetin on the progression of breast cancer in mice with chronic stress by regulating the polarization of microglia
CN101653607B (zh)	2013-02-13	含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
CN101601669B (zh)	2011-05-04	用于治疗肿瘤的联合用药物
CN1056082C (zh)	2000-09-06	一种抗癌药